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Two genetically distinct infectious recombinant virus clones (pMLV, constructed from Ingelvac® PRRS MLV and pMN184, constructed from
virulent strain MN184) were developed to study attenuation of contemporary porcine reproductive and respiratory syndrome virus (PRRSV) strain
MN184. Two reciprocal chimeric clones (pMLVORF1/MN184 and pMN184ORF1/MLV) were then constructed, such that the 5′UTR/ORF1 of
one genotype was linked to ORF2–7/3′UTR from the other genotype. In vitro studies demonstrated that the rescued chimeric viruses possessed
intermediate growth properties compared to recombinant rMLV and rMN184. Swine inoculation with rMN184 and rMLV verified that these
viruses fully mimicked the respective parent virus. In addition, earlier and higher antibody responses were detected in animals infected with
rMN184 in contrast to those infected with rMLV. Chimeric virus treatment groups showed similar antibody responses as seen with these parent
viruses, but much less severe pathogenesis when compared to the rMN184 group. These data suggested that genetic aspects of Ingelvac® PRRS
MLV 5′UTR/ORF1 replicase region and/or the structural proteins/3′UTR can serve to attenuate virulent strain MN184. The data also indicated
that designed PRRSV vaccines could be developed, keeping the known 5′UTR/replicase region of an early vaccine strain such as Ingelvac® PRRS
MLV intact, but replacing the structural protein/3′UTR domain with that of an emerging virulent virus.
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Porcine reproductive and respiratory syndrome virus
(PRRSV) is single-stranded positive-sense RNA virus (15–
15.5 kb) belonging to family Arteriviridae, order Nidovirales
(Cavanagh, 1997). The PRRSV genome consists of a short 5′
untranslated region (UTR) followed by nine open reading
frames (ORFs). ORFs 1a and 1b cover three-fourths of the
genome and translate into the replicase polyprotein 1a (pp1a)
and, less efficiently, pp1ab by means of a ribosomal frameshift
near the C terminus of ORF1a. The replicase polyprotein is
processed by self-cleavage into at least 13 nonstructural proteins⁎ Corresponding author. USDA-ARS B-14, Virus and Prion Diseases of
Livestock Research Unit, National Animal Disease Center, 2300 Dayton
Avenue, Ames, IA 50010, USA. Fax: +1 515 663 7259.
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doi:10.1016/j.virol.2007.09.032(nsps) that are likely involved in virus replication and
transcription (Meulenberg, 2000). The remaining ORFs (2a,
2b and 3–7) are mostly overlapping and code for viral structural
glycoprotein (GP) 2a, GP3, GP4, GP5, unglycosylated 2b/E and
membrane (M) proteins and a nucleocapsid protein (N). The 3′
terminus of the genome is made up of an UTR followed by a
poly-A tail (Meulenberg et al., 1993a,b; Snijder and Meulen-
berg, 1998; Nelsen et al., 1999; Wu et al., 2001). Based on
genetic differences, PRRSV isolates have been divided into
European (EU genotype, Type 1, prototype Lelystad) and North
American (US genotype, Type 2, prototype VR-2332) groups,
which typically exhibit ∼60% nucleotide similarity over the
entire genome.
PRRSV is the causative agent of porcine reproductive and
respiratory syndrome (PRRS), characterized as reproductive
failure in pregnant sows and respiratory problems in growing
swine. PRRS has caused substantial economic losses to the
419Y. Wang et al. / Virology 371 (2008) 418–429swine industry worldwide. In order to control this disease,
researchers have developed several different modified-live as
well as killed vaccines (Mengeling et al., 1996; Christopher-
Hennings et al., 1997; Dee and Joo, 1997; Plana-Duran et al.,
1997). However, PRRSV isolates are biologically, antigenically
and genetically heterogeneous and can also produce diverse
clinical severities (Halbur et al., 1995b; Mengeling et al., 1996;
Mateu et al., 2003; Labarque et al., 2004; Pesch et al., 2005;
Han et al., 2006). In addition, PRRSV evolves quickly through
simple mutation as well as recombination (Kapur et al., 1996;
Murtaugh et al., 1998; Yuan et al., 1999), such that conventional
vaccines often do not provide complete protection against het-
erologous challenge (Foss et al., 2002; Labarque et al., 2003;
Meier et al., 2003; Charerntantanakul et al., 2006; Diaz et al.,
2006). To control this disease more effectively, it is important to
identify PRRSV virulence factors and informatively develop
new vaccines. In earlier studies solely based on viral genome
comparisons, researchers sought to identify regions that would
determine viral virulence or attenuation (Oleksiewicz et al.,
1999; Allende et al., 2000; Yuan et al., 2001; Grebennikova
et al., 2004). However, individual genome determinants directly
involved in virulence and/or attenuation have not yet been elu-
cidated for any isolate, and the basis of PRRSVattenuation may
be strain-specific and possibly complex, as shown for strains of
both A and B influenza viruses (Snyder et al., 1988; Hoffmann
et al., 2005).
The construction and evaluation of chimeric viruses are
valuable approaches to solve this problem, and can provide new
insights into viral virulence and attenuation, in addition to
pathogenicity and immunogenicity. Virus isolate sequences are
now straightforwardly obtained and recombinant DNA techni-
ques offer a rapid way to modify the virus via combination of
different domains from two or several isolates. The first step
toward modifying PRRSV is to generate infectious cDNA
clones, which has been documented for several isolates
(Meulenberg et al., 1998; Dobbe et al., 2001; Nielsen et al.,
2003; Truong et al., 2004; Lee et al., 2005; Fang et al., 2006;
Kwon et al., 2006; Schommer and Kleiboeker, 2006). However,
few reports seek to modify the virus to elucidate the pathogenic
and/or immunological properties of PRRSV, leading to the
development of innovative vaccine candidates. Recently, a few
successful live attenuated vaccine candidates for human viruses
were produced by replacing one or more genes in their
respective infectious clones with corresponding viral genes
from closely related viruses (Whitehead et al., 1999; Durbin et
al., 2000; Skiadopoulos et al., 2002; Pham et al., 2005; Pletnev
et al., 2006; Blaney et al., 2007). In the present study, a similar
strategy was used to modify MN184, a highly pathogenic
isolate which appeared suddenly in geographical regions of
North America in 2002 and has caused severe reproductive
disease and high mortality (Han et al., 2006). The donating
genome was PRRSV Ingelvac® PRRS MLV, the first
commercial attenuated modified-live vaccine (Yuan et al.,
2001). Thus, these two viruses possess markedly different
virulence traits. On a nucleotide basis, the ORF1 nsp domains
share only 78.5% identity between these viruses, and the
structural protein genes are 90.0% identical.In this study, we prepared an infectious clone of strain
MN184, one clone of Ingelvac® PRRS MLV and two
subsequent chimeras, and fully characterized their properties
in vitro as well as in vivo. Virulent strain MN184 was attenuated
by replacement of either the 5′UTR/ORF1 replicase or the
structural genes/3′UTR sections of the MLV genome. The
results signify that separate regions of both genetic domains can
act individually to modify the virulence of strain MN184,
perhaps due to an interaction between the separate genetic
elements and/or their protein products.
Results
Generation of viruses
Two PRRSV full-length cDNA clones, pMLVand pMN184,
were constructed in the M-pOK12 vector (Fig. 1) from the
Ingelvac® PRRS MLV vaccine strain and a wt MN184 virulent
isolate, respectively. Clone pMLV had 11 nucleotide differences
(one nonconservative and one conservative amino acid subs-
titution; Table 1) and pMN184 contained six nucleotide changes
(one conservative amino acid substitution; Table 2). To verify
whether these two cDNA clones were infectious, linearized
pMLVand pMN184 were transcribed in vitro, and the synthetic
RNAs were subsequently transfected into MA-104 cells. Day 3
post-transfection, CPE appeared in both clones indicating that
the minor nucleotide/amino acid differences did not have a
noticeable effect on the in vitro growth properties of the
recombinants. IFA studies indicated that the transfected cells
possessed high levels of N protein expression for both
infectious clones (Fig. 2) and sequence analyses confirmed
that these two viruses were recovered from the respective
recombinant PRRSV (data not shown).
Using the unique EcoRV restriction enzyme site near the
beginning of the ORF2a gene of pMLV and pMN184, two
chimeric PRRSV cDNA clones were assembled (Fig. 1). Clone
pMLVORF1/MN184 held the 5′UTR and ORF1 replicase
domain of Ingelvac® PRRS MLV and the structural protein
domain and 3′UTR of wt MN184; clone pMN184ORF1/MLV
represented the inverse of clone pMLVORF1/MN184. The in
vitro derived RNA transcripts were individually transfected into
MA-104 cells. Three days post-transfection, CPE developed
from both of the chimeric RNAs, indicating that these two
infectious chimeric clones were viable. Compared to the
parental infectious clones, CPE from the two chimeric clones
appeared later than pMLVand earlier than pMN184. IFA results
indicated that two chimeras expressed N protein in a similar
manner as the parental viruses (Fig. 2).
To verify whether these four rescued viruses (rMLV,
rMN184, rMLVORF1/MN184 and rMN184ORF1/MLV) were
of recombinant origin, all viral RNAs of passage 3 were
analyzed. Full-genome sequencing results showed that recov-
ered virus rMLV and rMN184 maintained the nucleotide
sequence of the original plasmids pMLV and pMN184, respec-
tively, with no additional mutations seen. The genome structures
of two recovered chimeric viruses were exactly as designed, as
verified by sequence analysis of approximately 4 kb of the 5′
Fig. 1. MLV genome schematic and assembly diagram of four PRRSV full-length cDNA clones. All clones encode a T7 promoter and an intermediate guanosine
residue followed by the viral genome and a poly (A) tail of 30 residues. Unique restriction enzyme sites used in genetic manipulations are also shown. Sequences
contained in each of the fragments correspond to nucleotide position in the respective clone. (A) Assembly of pMLV. Fragment I (nt 1–4546), fragment II (nt 4547–
7592), fragment III (nt 7593–12,710) and fragment IV (nt 12,711–15,452). (B) Assembly of pMN184. Fragment I (nt 1–2497), fragment II (nt 2498–7199), fragment
III (nt 7200–11,075) and fragment IV (nt 11,076–15,058). (C) Assembly of pMLVORF1/MN184. (D) Assembly of pMN184ORF1/MLV. The generation of the
chimeric viruses utilized a common EcoRV restriction site at nt 12,613 of Ingelvac® PRRS MLV and nt 11770 of wt MN184.
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that the four rescued viruses were indeed derived from the
respective recombinant clone and all were stable when prop-
agated on MA-104 cells. The sequences of these four full-length
infectious clones were subsequently deposited in GenBank
(accession nos. EF484031–EF484034).
Growth properties of the chimeric viruses in cell culture
To evaluate the ability of the chimeric viruses to grow in vitro,
MA-104 cells were infected with chimeras in parallel with their
parental rMLV and rMN184 as well as Ingelvac® PRRS MLVTable 1
Nucleotide and amino acid differences between Ingelvac® PRRSMLVand pMLV
Nucleotide Location Ingelvac®
PRRS MLV
pMLV Amino acid
change
64 5′UTR T C –
480 Nsp1a A G Silent
7971 Nsp9 C A Silent
8643 Nsp9 A G Silent
10,641 Nsp10 G A Silent
11,220 Nsp11 C T Silent
11,250 Nsp11 C T Silent
11,987 Nsp12 G A Silent
13,403 GP3 G A G to D⁎
13,562 GP4 T C Silent
13,581 GP4 T G F to V
The nonconservative amino acid change is indicated by an asterisk (⁎).vaccine and wt MN184. Supernatant samples were harvested at
different time points and analyzed for viral yield in parallel by
plaque titration (Fig. 3A). rMLV and rMN184 had similar
replication properties to their parental viruses. The two chimeric
viruses displayed a rate of growth slower than rMLV, but a higher
growth rate than rMN184. At 60 h postinfection, the two chimeras
grew to a peak titer of 2.1×106 and 6.0×105 PFU/ml, respec-
tively, which was 5–20-fold less than the peak titer of rMLV
(1.1×107 PFU/ml). rMN184 reached its highest titer at 84 h
(4.4×105 PFU/ml). This indicated that the two chimeric viruses
and the vaccine isolates were better adapted for replication on
MA-104 cells than rMN184 and wtMN184. The plaque sizes of
the chimeric viruses reflected the replication kinetics to some
degree (Fig. 3B). rMLVORF1/MN184 resulted in plaques smaller
than rMLV, but much larger than rMN184. Plaques formed by
rMN184ORF1/MLV were considerably reduced in size in
comparison to rMLV, but slightly larger than the rMN184. The
data suggest that some aspect of the entire genome of both
chimeric constructs contributed to the kinetics of viral growth.
However, the plaque morphology appeared to be dictated by the
5′ four fifths of the genome, as rMLVORF1/MN184 plaques were
large and definitive while rMN184ORF1/MLV plaques exhibited
a diffuse characteristic, similar to rMN184.
To further examine the replication properties of the chimeric
viruses, a Northern blot assay (Fig 3C) was performed using a
32P-radiolabeled probe complementary to ORF7 (Yuan et al.,
2000). Analysis of vRNA transcripts derived from 2-day-
infectedMA-104 cell total RNA (m.o.i. 0.01) showed that rMLV
Table 2
Nucleotide differences between wt MN184 and pMN184
Nucleotide Location wt MN184 pMN184 Amino acid change
1396 Nsp2 C T Silent
2494 Nsp2 T C Silent
6307 Nsp5 T C Silent
7189 Nsp8 A G Silent
7195 Nsp8 T A Silent
9956 Nsp10 T C L to P
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RNA replication as their parental strains. The strength of
hybridization of vRNAs for the two chimeras was intermediate
between rMLV and rMN184, as seen with the one-step growth
curve. The vRNAwas isolated from an equal amount of infected
cells at the same time point, and since the chimeras both
displayed intermediate replication, this suggested that inherent
interactive properties of each chimeric genome played a
modifying role in virus replication. Interestingly, heteroclite
species were noted as previously described in Ingelvac® PRRS
MLVand rMLV, but not in the other viruses includingwtMN184
(Yuan et al., 2000, 2004).
Immunogenicity and replication of chimeric and parental
viruses in pigs
Eight groups of 5–15 pigs were coded to provide
anonymity during sample testing and then inoculated. Serum
samples, collected from all pigs on 0, 3, 5, 7, 14, 21, 24, 26,Fig. 2. Indirect immunofluorescent staining of viruses using PRRSV-specific monoc
Ingelvac® PRRS MLVor (D) wt MN184, or transfected with in vitro synthesized RN
or (F) pMN184ORF1/MLV. At 48 h after transfection or infection, cell monolayer28 and 35 dpi were assayed for anti-PRRSV antibody by
ELISA and then averaged for each group (Fig. 4). All animals
were seronegative to PRRSV through 7 days dpi. Throughout
the whole study, group 1 (infected with rMLV) and group 2
(infected with rMN184) had similar antibody responses
(antibody titer and response time) to the parental virus
Ingelvac® PRRS MLV vaccine (group 6) and wt MN184
(group 5) (all p valuesN0.05), respectively. Thus, rMLV and
rMN184 completely mimicked the serological immune
responses of the parental virus Ingelvac® PRRS MLV and
wt MN184 in vivo. By 21 dpi, chimeric virus-inoculated
pigs (groups 3 and 4) were seropositive to PRRSV and
remained seropositive throughout the study, with no signifi-
cant difference from virulent groups (2 and 5) among mean S/
P ratios (pN0.05), but had earlier and higher immune
responses than MLV vaccine groups (1 and 6) (pb0.05).
After challenge on day 21, mean S/P ratios of all virus-
treatment groups (1–6) were higher than challenge control
group (significance pb0.05). Swine in the challenge group
became seropositive on 35 dpi [14 day post challenge (dpc)]
while swine in the negative control group were seronegative
throughout the study.
To assay the ability of the two chimeric viruses to replicate
in vivo, the percentage of serum samples positive by virus
isolation was evaluated (Table 3). All serum samples from
pigs infected with chimeric virus rMN184ORF1/MLV (group
3) had detectable levels of virus at 3 dpi in MA-104 cells,
when viral isolation reached 100% percent, just like the serum
samples from the virulent virus groups (rMN184 and wtlonal antibody SDOW17. MA-104 cells were infected with (A) parental virus
A transcripts derived from (B) pMLV, (C) pMLVORF1/MN184, (E) pMN184
s were fixed and examined for PRRSV N protein expression.
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rMLVORF1/MN184 (group 4) were viremic at 5 dpi. The
percent of serum samples that were viremic based on virus
isolation from vaccine groups reached peaks of 86.7% at 5 dpi
(Ingelvac® PRRS MLV, group 6) and of 66.7% at 7 dpi(rMLV, group 2), slightly later in the course of infection
compared with other viruses investigated. These data indicated
that the chimeric viruses replicated much more vigorously
than the MLV vaccine-like viruses in pigs. After challenge
with the heterologous virulent isolate SDSU 73, 21 days after
exposure to the initial group of viruses, all challenge control
pigs were virus-positive at 24 dpi (3 dpc), and the other virus
treatment groups had no significant changes except the rMLV
group that reached another virus-positive peak 100% at 26 dpi
(5 dpc), suggesting that immunological exposure to the
initially inoculated viruses appeared to limit the replication
of the challenge virus.
To further evaluate quantitative levels of viral replication,
serum samples at 7 and 21 dpi were determined by real-time RT-
PCR (Fig. 5). The RNA copy numbers from groups 1–7 were
somewhat higher at 7 dpi (Fig. 5A) than at 21 dpi (Fig. 5B),
which indicated that all circulating viruses were exhibiting
typical PRRSV replication. Animals infected with rMLV (group
1) and rMN184 (group 2) had a similar virus level as pigs
exposed to their respective parent virus (pN0.05; no significant
difference). This indicated that virus rMLV and rMN184 fully
mirrored the replication properties of Ingelvac® PRRS MLV
and wt MN184 in vivo, respectively. The replication levels of
the two chimeras were intermediate between those of the
parental strains, and comparison of the means indicated that the
growth rate of both chimeras was significantly different from
the parental strains, rMLVand rMN184 (each p valueb0.0001).
Viral load from pigs infected with chimera rMN184ORF1/MLV
was higher than those of rMLVORF1/MN184, but the
difference was not significant (pN0.05). Thus, the high level
of viremia seen with rMN184 was dramatically reduced (≥2
log10/ml) when either the 5′UTR/ORF1 or the ORF2–7/3′UTR
viral sequences were replaced with those of MLV.
Sequence analysis of RT-PCR products of infected sera of
two animals per group at day 7 showed that the swine were
infected with the intended virus and not from environmental or
laboratory contamination, and no additional mutations were
found in the amplified PCR products (data not shown). These
data suggested that the chimeras and their parental viruses were
stable during replication in pigs.
Differences in clinical signs exhibited by swine infected with
parental and chimeric viruses
General observations before challenge were recorded
(Table 4). All pigs infected with virulent viruses (rMN184Fig. 3. Growth characterization of rescued viruses in MA-104 cells. (A) One-
step growth curves. The results are expressed as mean values from two
independent experiments. (B) Plaque phenotypes of all six viruses were stained
with crystal violet. (C) Northern blot hybridization of total RNAs isolated from
MA-104 cells infected with parental virus Ingelvac® PRRSMLV (lane 1) and wt
MN184 (lane 4), and the third passages of PRRSV rMLV (lane 2), rMLVORF1/
MN184 (lane 3), rMN184 (lane 5) and rMN184ORF1/MLV (lane 6) at an m.o.i.
of 0.01. RNA samples were hybridized with P32-radiolabeled probe comple-
mentary to PRRSV ORF7. mRNA numbers 1 to 6, 7–1 and 7–2 represent the
PRRSV-specific mRNA species (mRNA 1 represents the genome). RNA sizes
were evaluated with an RNA marker (Invitrogen), shown on the right.
Fig. 4. Mean PRRS ELISA 2XR S/P ratios. Dashed line at 0.4 S/P ratio designates
threshold value above which titers are considered positive for anti-PRRSV
antibodies. Challenge virus inoculation on day 21 is indicated by the hashed arrow.
423Y. Wang et al. / Virology 371 (2008) 418–429and wt MN184) developed typical clinical signs of PRRS,
such as labored breathing, lameness, emaciation and depres-
sion, and in some cases death. Conversely, only mild coughing
and slightly swollen legs were observed in one pig per group
of the swine inoculated with the chimeras, each eventually
returning to a healthy state.
Differences in gross lung lesions exhibited at necropsy by
swine infected with parental and chimeric viruses
Average lung lesion scores on 14 dpi, derived from a subset
of animals from each treatment group, is shown in Fig. 6A. The
pigs infected with virulent strain (rMN184 and wt MN184,
groups 2 and 5) had significantly higher (pb0.05) average lung
lesion scores than all other groups except group 3 (infected with
chimeric virus rMN184ORF1/MLV) (pN0.05). In group 3, 2/5
pigs developed severe lung lesions. Only mild lung lesions were
observed in 2/5 pigs inoculated with rMLVORF1/MN184 virus
as well as 1 pig/group receiving rMLV and Ingelvac® PRRS
MLV (groups 1 and 4, respectively), and the average lung lesion
scores from all animals in this latter grouping were similar (each
pN0.05).Table 3
Virus isolation from serum samples from all animals remaining in each group at all
Group Virus Virus isolation (%)
Day 0 Day 3 Day 5 Day 7
1 rMLV 0 26.7 60 66.7
2 rMN184 0 100 100 100
3 rMN184ORF1/MLV 0 100 100 92.9
4 rMLVORF1/MN184 0 86.7 100 100
5 wt MN184 0 100 100 92.9
6 Ingelvac® PRRS MLV 0 73 86.7 86.7
7 Challenge control 0 0 0 0
8 Negative control 0 0 0 0
Challenge virus was given on day 21 after sampling of serum.After virulent PRRSV SDSU 73 challenge on 21 dpi, 7/18
pigs previously infected with a virulent strain (rMN184 and wt
MN184) succumbed to the virus, and one pig in the challenge
control group also died (Table 4). The clinical observations of all
remaining animals were again evaluated daily following virulent
challenge (Fig. 6B). Swine with the highest average clinical
scores were from virulent group 5 (wt MN184), similar to
rMN184 (group 2; pN0.05), which were significantly increased
over the other six groups (pb0.001). The two chimera groups
had similar clinical values to the vaccine groups (rMLV and
Ingelvac® PRRS MLV) (pN0.05), and the average clinical
scores from these four groups were lower than challenge control
group (each p valueb0.05). The strict negative control pigs did
not exhibit clinical signs.
Differences in average daily weight gain seen in swine infected
with parental and chimeric viruses
The average daily weight gain (ADG) in each group was
evaluated between 0 and 14, 14 and 21 (day of challenge), and
21 and 35 dpi (Fig 6C). On day 0 there was no significant
difference in the weight of any of the eight groups (pN0.05; data
not shown). However, after initial virus inoculation, the animals
exposed to the chimeras were statistically equivalent to the
vaccine groups (rMLV and Ingelvac® PRRS MLV), the chal-
lenge control group and the negative control group (pN0.05).
Pigs infected with virulent virus (rMN184 and wt MN184) had
significantly lower ADG than all other groups (pb0.0001).
These findings were also recorded for the second period of
measurement, but less so for the last two weeks (21–35 dpi).
These data showed that both chimeric viruses did not result in
the severe weight loss seen with MN184 isolates.
Discussion
A facile method for investigating PRRSV viral attenuation
was developed. For these initial studies, the first recombinant
clones of Ingelvac® PRRSMLVand a recently emergedMN184
isolate were fully characterized. The cell culture properties,
along with the pathogenic and immunogenic profiles of these
recombinant viruses fully mimicked those of the parental
isolates. Subsequent production of two novel PRRSV chimeras,
from viruses that possess only 87% nucleotide similarity at thetime points
Day 14 Day 21 Day 24 Day 26 Day 28 Day 35
33.3 40 90 100 90 30
92.9 70 62.5 75 50 16.7
100 70 40 40 50 30
100 40 90 80 60 22
92.3 75 80 60 60 25
80 60 80 70 70 40
0 0 100 100 100 55.6
0 0 0 0 0 0
Fig. 5. Viral load in serum of pigs at 7 dpi (A) and 21 dpi (B) after intramuscular
inoculation with 2×104.7 TCID50 of rMLV, rMN184, rMN184ORF1/MLV,
rMLVORF1/MN184, wt MN184, Ingelvac® PRRS MLV vaccine and no
treatment. Viral titers were determined by real-time RT-PCR and represented as
viral RNA copies/ml serum. At 7 dpi and 21 dpi, rMN184ORF1/MLV and
rMLVORF1/MN184 had similar mean load in pigs (pN0.05), replicated to
higher titers than rMLVor Ingelvac® PRRS MLV (⁎⁎⁎pb0.0001) and to lower
titers than rMN184 or wt MN184 (⁎⁎⁎pb0.0001). Each dot is from analysis of
serum from one pig and bars represent the mean values of the different treatment
groups. Eight to fifteen pigs were evaluated for each group.
Table 4
Clinical observations for all experimental groups
Group Virus strain Mortality
before and
after
challenge
Days of death
(dpi) before
and after
challenge
General
observations
before
challenge
Before After Before After
1 rMLV 0/15 0/10 N N 15/15—healthy
2 rMN184 2/15 4/10 3, 11 21, 21,
29, 29
15/15—cough,
thin, lame,
depressed
3 rMN184ORF1/
MLV
0/15 0/10 N N 1/15—thin
and coughing,
recovered
4 rMLVORF1/
MN184
0/15 0/10 N N 1/15—swollen
leg, recovered
5 wt MN184 3/15 3/8 6, 14,
14
21, 22,
28
15/15—depressed,
thin, panting
6 Ingelvac®
PRRS MLV
0/15 0/10 N N 15/15—healthy
7 Challenge
control
0/15 1/10 N N 15/15—healthy
8 Negative
control
0/10 0/10 N N 10/10—healthy
Challenge virus was given on day 21 after sampling of serum.
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might be artificially recombined at strategic locations within the
PRRSV genome. Thus, a molecular strategy was established to
investigate genomic regions potentially involved in virulence or
attenuation domains and to develop novel vaccine prototypes
against constantly emerging PRRSV.
The chimeric virions possessed in vitro phenotypic proper-
ties that were comparable to naturally derived PRRSV.
Noticeably, the chimeras replicated faster than rMN184 or wt
MN184, but at a reduced rate when compared to Ingelvac®
PRRS MLV. This observation is likely due to the fact that thechimeras possess a part of the MLV genome, which had
previously been adapted to replicate efficiently in MA-104 cells
by continuous passage of the PRRSV NA prototype isolate VR-
2332. Previous research has shown that attenuated viruses
appear to replicate well on MA-104 cells (Botner et al., 1999).
Since rMN184ORF1/MLV and rMLVORF1/MN184 replicated
more robustly than virulent rMN184, this alone may indicate
possible in vivo attenuation of PRRSV. Because the chimeras
were derived with either the 5′UTR/ORF1 or the ORF2–7/3′
UTR of faster replicating MLV virus, the data suggest that more
than one segment of the genome may contribute to the final viral
replication rate, or that some interactive aspect of the entire
genome contributes to the increased kinetics of viral growth.
Lastly, the plaque morphology seemed to be determined by the
5′ three fourths of the genome (replicase domain) and not the 3′-
end structural proteins.
In swine, the infectious clone rescued virus (rMN184) is highly
pathogenic, just like wtMN184, resulting in death of 6 out of 15
animals and typical PRRS-associated disease was noted in the
remaining animals. However, swine that received rMLVORF1/
MN184 displayed a course of infection that was very similar to
that observed for the attenuated rMLV virus. All of these animals
survived and failed to demonstrate any major clinical symptoms,
even though viral infection was confirmed. The difference
between rMLVORF1/MN184 and the parental rMN184 was the
5′UTR/ORF1 domain exchange. Therefore, the complete loss of
acute pathogenicity by introducing the 5′ four-fifths of the vaccine
virus demonstrates the importance of this domain in attenuation.
In contrast, although all rMN184ORF1/MLV-inoculated animals
exhibited attenuated pathogenesis compared to its rMN184
parent, the virus still produced more severe lung lesions than
that observed for rMLVORF1/MN184 (Fig. 6A). After challenge,
it was clear that the groups infected with the chimeric viruses had
425Y. Wang et al. / Virology 371 (2008) 418–429less serious average clinical scores (similar to rMLV group) when
compared to rMN184-infected and challenge control groups
(Fig. 6B). Therefore, the results strongly suggested that these two
chimeric viruses can protect to a large degree against heterologous
SDSU73 virulent virus challenge.
Quantitative real-time RT-PCR (Fig. 5) showed that viremia
levels varied significantly within individual groups, indicating
that the growth rate of PRRSV in pigs is possibly due to
variation in susceptibility to infection. Virulent virus MN184
replicates faster than attenuated virus Ingelvac® PRRS MLV in
vivo, although propagation was reversed in MA-104 cells.
Johnson et al. also noted that virulent PRRSV isolates grew to
significantly higher levels in vivo than cell-culture adapted
isolates (Johnson et al., 2004). Chimeric viruses rMN184ORF1/
MLV and rMLVORF1/MN184 exhibited intermediate growth
properties when compared to virulent virus MN184 and cell-
culture attenuated virus Ingelvac® PRRS MLV. rMN184ORF1/
MLV exhibited slightly elevated levels of viremia when
compared to rMLVORF1/MN184. This suggests that the
ORF1 replicase domain has more of an effect on viral growth
properties than the structural protein region, as noted in the
plaque morphologies of the chimeric viruses, although further
studies are required. The two chimeras also stimulated an earlier
and moderate-to-high level of serum antibodies against PRRSV,
similar to the highly virulent isolate MN184, and were
significantly higher than the vaccine viruses (pb0.05).
Within the swine industry, there are those who are attempting
to use live virulent PRRSV inoculation (LVI) as a mechanism to
induce protective immunity. Although not the intended purpose
of this investigation, it is interesting to note that treatment groups
that received rMN184 and wt MN184 did have safety issues
including mortality both prior and following virulent challenge
exposure. In contrast, the clones derived, totally or in part, from
attenuated virus had improved safety (no mortality) and
appeared to be protected following the heterologous virulent
challenge exposure. This suggests that the LVI technique should
be reconsidered for both safety reasons and the fact that
improved immunity and protection may not be realized.
In conclusion, the two chimeric viruses possessed substan-
tially different growth characteristics and stimulated intermedi-
ate serological immune responses when compared to the
parental viruses Ingelvac® PRRS MLV and MN184. This then
signifies that both the 5′UTR/replicase domain and structuralFig. 6. Effects of chimeric and parental viruses on swine. Average lung scores
were recorded at 14 dpi (A). The results are expressed as mean values of gross
lung lesions from 5 to 10 pigs in each group, and error bars represent standard
errors of mean values from different pigs. An asterisk indicates the average lung
score of this set is higher than the challenge control (⁎pb0.05). (B) Clinical
observations of each pig were evaluated daily from 21 dpi, when the swine were
challenged with heterologous virulent PRRSV SDSU73, to 35 dpi. The error
bars represent standard errors of mean values from different pigs at different
days. Asterisks (⁎⁎/⁎⁎⁎) indicate that the average clinical score of the treatment
set is significantly higher than the set included with the negative control
(pb0.001 or pb0.0001). (C) All experimental pigs were weighed at 0, 14, 21
and 35 dpi. The average daily weight gain (ADG) from 5 to 15 pigs in each group
was calculated at period of 0–14, 14–21 and 21–35 dpi. The error bars represent
standard deviation. An asterisk (⁎) represents the ADG of this group is lower
than the other groups (pb0.05).
426 Y. Wang et al. / Virology 371 (2008) 418–429protein/3′UTR domain, or the full genomic interplay can
regulate viral replication and/or play a role in protein processing
and viral maturation and ultimately virulence in swine. Since
sequence alignment between Ingelvac® PRRS MLV and its
parental virulent isolate VR-2332 showed that both the 5′UTR
and 3′UTR are identical (data not shown), we surmise that the
nonstructural and structural protein regions of PRRSV may play
the more important role in attenuation in this study.
The development of new PRRSV vaccines may be modeled
on this study, such that the 5′UTR and ORF1 replicase originate
from Ingelvac® PRRSMLVor other vaccines, and the structural
protein and 3′UTR domain originate from highly virulent
viruses that may arise in the future.
Materials and methods
Cells and viruses
MA-104 cells (ATCC CRL2621) were cultured in minimum
essential medium (EMEM, JRH 56416) with 10% fetal bovine
serum (Invitrogen) at 37 °C, 5% CO2. PRRSV vaccine
Ingelvac® PRRS MLV (GenBank accession no. AF066183)
and wild-type (wt) isolate MN184 (GenBank accession no.
EF488739) were used to construct the infectious clones and the
chimeras. PRRSV isolate SDSU73 was used as a heterologous
challenge virus for the swine studies. The conventional or the
rescued recombinant viruses were used to infect MA-104 cells.
When observed cytopathic effect (CPE) was approximately
80%, virus was harvested from the supernatant, followed by
removal of cell debris by centrifugation.
Construction of cDNA clones of PRRSV
All the molecular constructs were prepared by using standard
molecular biological techniques, i.e., by insertion of a viral RT-Table 5
Primers used in preparation of PRRSV infectious clones
Primer Sequence
MLV T7leader/ 5′-ACATGCATGCTTAATACGACTCACTATAGTAT
/MLV3′–4545 5′-CTGGGCGACCACAGTCCTA-3′
MLV5′–4056/ 5′-CTTCTCGGCGCGCCCGAATGGGAGT-3′
/MLV3′–7579 5′-TCATCATACCTAGGGCCTGCTCCACG-3′
MLV5′–7579/ 5′-CGTGGAGCAGGCCCTAGGTATGATGA-3′
/MLV3′–13,293 5′-TGCAGGCGAACGCCTGAG-3′
MLV5′–11,938/ 5′-GTGAGGACTGGGAGGATTACA-3′
/MLV3′-end 5′-GTCTTTAATTAACTAG(T)30AATTTCG-3′
MN184 T7leader/ 5′-AGATGGCCGGCCTTAATACGACTCACTATAG
/184–2478 5′-TCGCTCGAGCTTGCCACCAACTCAGGTA-3′
184–2494/ 5′-AAGCTCGAGCGAGCCTGTGCCTGTC-3′
/184–7181 5′-ATACCTAGGGCCTGCTCCATGGAAAG-3′
184–7195/ 5′-GGCCCTAGGTATGATGAACGTTGAC-3′
/184–12,237 5′-GGGAAAATAGCAAACACCTGTTCTAGAG-3′
184–12,215/ 5′-GTAACCATAGTGTATAATAGCTCTCTAGAAC
/184–13,002 5′-GGACGAGTGGCCATGCCTAAGACA-3′
184–12,946/ 5′-TAAGACCAACACCACCGCA-3′
/184–3′-end 5′-GTCTTTAATTAACTAG(T)30AATTTCGGC-3′
Forward primers indicated by a slash (/) following the name and reverse primers h
construction are indicated by an asterisk (⁎). Only the AvrII site used in pMN184 clPCR product into the corresponding site of the modified pOK12
vector with added restriction enzyme sites (M-pOK12;
GenBank accession no. EF484035). Four generated RT-PCR
fragments (Fig. 1; I–IV) for each virus (Ingelvac® PRRS MLV
and wt MN184) were digested and ligated into the M-pOK12
plasmid separately, followed by DNA sequencing. Quik-
Change®Multi Site-Directed Mutagenesis Kit (Stratagene)
was used to modify all cDNA subclones. The correct
nucleotides were confirmed by complete DNA sequencing.
Primers used to perform RT-PCR for preparation of full-length
cDNA clones of the two viruses have been listed in Table 5.
Two full-length cDNA clones, named pMLV and pMN184,
were generated (Fig. 1). Both cDNA clones possessed the T7
promoter at the 5′ termini followed by the viral genome and a
30-bp synthetic poly(A) tail. These two genomic recombinant
clones were fully sequenced to ensure that additional mutations
had not been introduced during cloning.
The 5′UTR and ORF1 domain or ORFs 2–7 and the 3′UTR
domain of Ingelvac® PRRS MLV were exchanged for those of
wt MN184. Clone pMLVORF1/MN184 possessed nucleotides
(nt) 1–12,163 of pMLV and nt 12,164–15,452 were from
pMN184, and clone pMN184 ORF1/MLV was the inverse of
the first chimeric construct (Fig. 1).
Recovery of viruses
The four cDNA clones were linearized with PacI and capped
RNA transcripts were synthesized using the mMessageMachine
Kit (Applied Biosystems). Confluent MA-104 cells were sep-
arately transfected with 2.5 μg of each individual RNA transcript
using DMRIE-C (Invitrogen) (Nielsen et al., 2003). The pres-
ence of PRRSV N protein was detected at day 2 postinfection
(pi) by indirect immunofluorescence assay (IFA) using mono-
clonal antibody SDOW17 (gift of Eric A. Nelson) (Magar et al.,
1997). The transfection supernatants were collected whenRestriction site
GACGTATAGGTGTTGGCTCTATGCCTTGG-3′ SphI⁎
FseI
FseI
AvrII
AvrII
BsrGI
BsrGI
PacI⁎
ATGACGTATAGGTGTTGGCTCTATG-3′ FseI⁎
XhoI
XhoI
AvrII⁎
AvrII⁎
BsrGI
AGG-3′ BsrGI
PstI
PstI
PacI⁎
ave a slash before the name. Restriction enzyme sites introduced during clone
one construction altered the original virus sequence, causing a silent mutation.
427Y. Wang et al. / Virology 371 (2008) 418–429CPE appeared, and the rescued viruses were named rMLV,
rMN184, rMLVORF1/MN184 and rMN184ORF1/MLV. Each
transfected cell culture was serially passaged three times. The
total RNA was extracted from passage 3 supernatant of
each rescued virus and analyzed by RT-PCR followed by
sequencing. Titers were determined on MA-104 cells by plaque
forming units (PFU)/ml to assess in vitro growth properties
(Yuan et al., 2000) and by TCID50/ml for in vivo inoculation
(Johnson et al., 2004).
Growth curve analysis
One-step growth curve analysis was completed as described
previously with each virus at an input multiplicity of infection
(m.o.i.) of 0.1 (Han et al., 2007). The virus titers of Ingelvac®
PRRS MLV, wt MN184, rMLV, rMN184, rMLVORF1/MN184
and rMN184ORF1/MLV at different time points were deter-
mined by plaque assay in MA-104 cells.
Northern blot analysis
Ingelvac® PRRS MLV, wt MN184 and the third passages of
rMLV, rMN184, rMLVORF1/MN184 and rMN184ORF1/MLV
were inoculated in MA-104 cells at an m.o.i. of 0.01. Two days
after infection, intracellular RNAwas extracted and electrophor-
esed (15 μg/sample) on a glyoxal denaturing gel as described
previously (Nelsen et al., 1999). After the RNA was transferred
onto a 0.45 μm MagnaGraph nylon transfer membrane
(Osmonics), the membrane was hybridized with a P32-radiola-
beled ORF7-specific oligonucleotide probe (Yuan et al., 2000).
In vivo infection
The in vivo studies were carried out at Boehringer Ingelheim
Vetmedica, Incorporated in Ames, IA. 115 healthy pigs, at
3 weeks of age, were obtained from a herd free of PRRSV
and randomly assigned to the following treatment groups: group
1—rMLV, group 2—rMN184, group 3—rMN184ORF1/
MLV, group 4—rMLVORF1/MN184, group 5—wt MN184,
group 6—Ingelvac® PRRS MLV, group 7—challenge control,
group 8—strict negative control. On day 0 all animals in groups
1–6 were inoculated intramuscularly with the respective
treatment (approximately 2×104.7 TCID50/pig). Swine were
observed daily for general health status and weighed at 0, 14, 21
and 35 days post-inoculation (dpi). Serum samples were co-
llected from all animals on 0, 3, 5, 7, 14, 21, 24, 26, 28 and
35 dpi for further analysis. Five animals in groups 1–7 were
necropsied at 14 dpi and lung scores recorded. The remaining
animals in groups 1–7 were exposed to a heterologous virulent
virus challenge (PRRSV SDSU 73, 2×103 TCID50/pig) at
21 dpi. On the ORF5 nucleotide level, SDSU 73 is 89.6%
similar to Ingelvac PRRS MVL and 87.2% similar to MN184.
Serology
All serum samples were examined for serological response
by use of a PRRS 2XR enzyme-linked immunosorbent assay,which utilizes recombinant PRRSV antigens (ELISA; IDEXX
Laboratories). A sample was considered positive for PRRSV
antibodies if the sample-to-positive (S/P) ratio was equal to or
greater than 0.4.
Viremia detection by virus isolation and quantitative real-time
RT-PCR
To determine if the animals were viremic, virus isolation
was performed with serum samples collected on days 0, 3, 5,
7, 14, 21, 24, 26, 28 and 35. Briefly, sera were inoculated into
MA-104 cells separately and the percent positive for CPE in
each group was calculated. Since virus isolation cannot
evaluate the load of PRRSV, real-time RT-PCR was performed
to further assess viremia. Sera collected at 7 and 21 dpi were
used to detect the RNA copy number of PRRSV by TaqMan-
based quantitative real-time RT-PCR for ORF6. In brief,
ORF6 of PRRSV was cloned into pGEM-T (Promega Cor-
poration), and in vitro transcription was performed to syn-
thesize ORF6 RNA using the RiboMAX™ Large Scale RNA
Production System - T7 (Promega Corporation). RNA copy
number was calculated using Avogadro's number (6.022×1023
copies/mole) divided by the molecular weight of one copy of
ORF6 (128,664 g/mol) to derive the number of copies per gram
of in vitro derived transcript (3.57×1018). The standard curve
was developed using serial 10-fold dilutions of the ORF6
transcripts (105 to 1010). Each serum sample was run in triplicate
and the mean RNA copy number calculated from these values.
Nucleotide sequencing
The recombinant parental and chimeric virus clones were
confirmed by complete genome sequencing. After in vivo
inoculation, RNA was extracted from the sera of selected pigs
in each treatment group. Targeted RT-PCR was performed and
the products were sequenced to confirm the origin of the
infecting virus by comparing the sequences recovered from
infected pigs to the sequences of the respective infectious
cDNA clones. Specifically, we sequenced approximately 1300
bases of the crossover region (3′ORF1–5′ORF2; MLV ref-
erence nt. 11,180–12,480) for the two chimeras. For the
recovered parent viruses, we sequenced bases 6710–7520 for
MN184 (in ORF1) and bases 11,370–12,500 (3′ORF1–5′
ORF2) for MLV.
Clinical evaluation
Lungs of the study animals were evaluated at necropsy for
evidence of gross lesions. Lungs were evaluated by the per-
centage of lesions noted per lobe, and then, using a standard
scoring system, an overall level of gross lung pathology was
determined (Halbur et al., 1995a). The clinical condition of the
animals was evaluated daily following virulent challenge (days
21–35). Observations included behavior, respiration and cough.
The clinical condition of these animals was evaluated based on a
numerical index that reflected the severity of illness. Scores for
each of three individual observations ranged from 1 to 4. The
428 Y. Wang et al. / Virology 371 (2008) 418–429observation score consists of the sum of the daily observations
for behavior, respiration and cough. For example, a clinically
normal animal would be given a total score of 3 (i.e., be-
havior=1, respiration=1, cough=1), an animal with maximum
clinical illness would be given a total score of 9 (i.e., behavior=3,
respiration=3, cough=3) and a dead animal would be given a
total score of 12 (i.e., behavior=4, respiration=4, cough=4).
Acknowledgments
The authors want to acknowledge the technical help con-
tributed by the personnel at Boehringer Ingelheim Vetmedica,
Incorporated, who also provided funds for this study. We also
would like to thank Marcus Kehrli, Jr. and Kelly Lager for their
critical review and helpful suggestions.
References
Allende, R., Kutish, G., Laegreid, W., Lu, Z., Lewis, T., Rock, D., Friesen, J.,
Galeota, J., Doster, A., Osorio, F., 2000. Mutations in the genome of porcine
reproductive and respiratory syndrome virus responsible for the attenuation
phenotype. Arch. Virol. 145, 1149–1161.
Blaney, J.J., Sathe, N., Hanson, C., Firestone, C., Murphy, B., Whitehead, S.,
2007. Vaccine candidates for dengue virus type 1 (DEN1) generated by
replacement of the structural genes of rDEN4 and rDEN4Delta30 with those
of DEN1. Virol. J. 4, 23.
Botner, A., Nielsen, J., Oleksiewicz, M., Storgaard, T., 1999. Heterologous
challenge with porcine reproductive and respiratory syndrome (PRRS)
vaccine virus: no evidence of reactivation of previous European-type PRRS
virus infection. Vet. Microbiol. 68, 187–195.
Cavanagh, D., 1997. Nidovirales: a new order comprising Coronaviridae and
Arteriviridae. Arch. Virol. 142, 629–633.
Charerntantanakul, W., Platt, R., Roth, J.A., 2006. Effects of porcine
reproductive and respiratory syndrome virus-infected antigen-presenting
cells on T cell activation and antiviral cytokine production. Viral Immunol.
19, 646–661.
Christopher-Hennings, J., Nelson, E., Nelson, J., Benfield, D., 1997. Effects of a
modified-live virus vaccine against porcine reproductive and respiratory
syndrome in boars. Am. J. Vet. Res. 58, 40–45.
Dee, S., Joo, H., 1997. Strategies to control PRRS: a summary of field and
research experiences. Vet. Microbiol. 55, 347–353.
Diaz, I., Darwich, L., Pappaterra, G., Pujols, J., Mateu, E., 2006. Different
European-type vaccines against porcine reproductive and respiratory
syndrome virus have different immunological properties and confer
different protection to pigs. Virology 351, 249–259.
Dobbe, J., Van Der Meer, Y., Spaan, W., Snijder, E., 2001. Construction of
chimeric arteriviruses reveals that the ectodomain of the major glycoprotein
is not the main determinant of equine arteritis virus tropism in cell culture.
Virology 288, 283–294.
Durbin, A., Skiadopoulos, M., Mcauliffe, J., Riggs, J., Surman, S., Collins, P.,
Murphy, B., 2000. Human parainfluenza virus type 3 (PIV3) expressing the
hemagglutinin protein of measles virus provides a potential method for
immunization against measles virus and PIV3 in early infancy. J. Virol. 74,
6821–6831.
Fang, Y., Faaberg, K., Rowland, R., Christopher-Hennings, J., Pattnaik, A.,
Osorio, F., Nelson, E., 2006. Construction of a full-length cDNA infectious
clone of a European-like Type 1 PRRSV isolated in the U.S. Adv. Exp. Med.
Biol. 581, 605–608.
Foss, D.L., Zilliox, M., Meier, W., Zuckermann, F., Murtaugh, M., 2002.
Adjuvant danger signals increase the immune response to porcine
reproductive and respiratory syndrome virus. Viral Immunol. 15, 557–566.
Grebennikova, T., Clouser, D., Vorwald, A., Musienko, M., Mengeling, W.,
Lager, K.M., Wesley, R.D., Biketov, S., Zaberezhny, A., Aliper, T.,
Nepoklonov, E., 2004. Genomic characterization of virulent, attenuated,and revertant passages of a North American porcine reproductive and
respiratory syndrome virus strain. Virology 321, 383–390.
Halbur, P., Miller, L., Paul, P., Meng, X., Huffman, E., Andrews, J., 1995a.
Immunohistochemical identification of porcine reproductive and respiratory
syndrome virus (PRRSV) antigen in the heart and lymphoid system of three-
week-old colostrum-deprived pigs. Vet. Pathol. 32, 200–204.
Halbur, P., Paul, P., Frey, M., Landgraf, J., Eernisse, K., Meng, X., Lum, M.,
Andrews, J., Rathje, J., 1995b. Comparison of the pathogenicity of two US
porcine reproductive and respiratory syndrome virus isolates with that of the
Lelystad virus. Vet. Pathol. 32, 648–660.
Han, J., Wang, Y., Faaberg, K., 2006. Complete genome analysis of RFLP 184
isolates of porcine reproductive and respiratory syndrome virus. Virus Res.
122, 175–182.
Han, J., Liu, G., Wang, Y., Faaberg, K., 2007. Identification of nonessential
regions of the nsp2 replicase protein of PRRSV strain VR-2332 for
replication in cell culture. J. Virol. 81, 9878–9890.
Hoffmann, E., Mahmood, K., Chen, Z., Yang, C., Spaete, J., Greenberg, H.,
Herlocher, M., Jin, H., Kemble, G., 2005. Multiple gene segments control
the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/
66. J. Virol. 79, 11014–11021.
Johnson, W., Roof, M., Vaughn, E., Christopher-Hennings, J., Johnson, C.,
Murtaugh, M., 2004. Pathogenic and humoral immune responses to porcine
reproductive and respiratory syndrome virus (PRRSV) are related to viral
load in acute infection. Vet. Immunol. Immunopathol. 102, 233–247.
Kapur, V., Elam, M., Pawlovich, T., Murtaugh, M., 1996. Genetic variation in
porcine reproductive and respiratory syndrome virus isolates in the
midwestern United States. J. Gen. Virol. 77, 1271–1276.
Kwon, B., Ansari, I., Osorio, F., Pattnaik, A., 2006. Infectious clone-derived
viruses from virulent and vaccine strains of porcine reproductive and
respiratory syndrome virus mimic biological properties of their parental
viruses in a pregnant sow model. Vaccine 24, 7071–7080.
Labarque, G., Van Gucht, S., Van Reeth, K., Nauwynck, H., Pensaert, M., 2003.
Respiratory tract protection upon challenge of pigs vaccinated with
attenuated porcine reproductive and respiratory syndrome virus vaccines.
Vet. Microbiol. 95, 187–197.
Labarque, G., Reeth, K.V., Nauwynck, H., Drexler, C., Van Gucht, S., Pensaert,
M., 2004. Impact of genetic diversity of European-type porcine reproductive
and respiratory syndrome virus strains on vaccine efficacy. Vaccine 22,
4183–4190.
Lee, C., Calvert, J., Welch, S.K., Yoo, D., 2005. A DNA-launched reverse
genetics system for porcine reproductive and respiratory syndrome virus
reveals that homodimerization of the nucleocapsid protein is essential for
virus infectivity. Virology 331, 47–62.
Magar, R., Larochelle, R., Nelson, E., Charreyre, C., 1997. Differential
reactivity of a monoclonal antibody directed to the membrane protein of
porcine reproductive and respiratory syndrome virus. Can. J. Vet. Res. 61,
69–71.
Mateu, E., Martin, M., Vidal, D., 2003. Genetic diversity and phylogenetic
analysis of glycoprotein 5 of European-type porcine reproductive and
respiratory virus strains in Spain. J. Gen. Virol. 84, 529–534.
Meier, W., Galeota, J., Osorio, F., Husmann, R., Schnitzlein, W., Zuckermann,
F., 2003. Gradual development of the interferon-gamma response of swine to
porcine reproductive and respiratory syndrome virus infection or
vaccination. Virology 309, 18–31.
Mengeling, W., Vorwald, A., Lager, K., Brockmeier, S., 1996. Comparison
among strains of porcine reproductive and respiratory syndrome virus for
their ability to cause reproductive failure. Am. J. Vet. Res. 57, 834–839.
Meulenberg, J., 2000. PRRSV, the virus. Vet. Res. 31, 11–21.
Meulenberg, J., De Meijer, E.J., Moormann, R., 1993a. Subgenomic RNAs of
Lelystad virus contain a conserved leader-body junction sequence. J. Gen.
Virol. 74, 1697–1701.
Meulenberg, J., Hulst, M., De Meijer, E.J., Moonen, P., Den Besten, A., De
Kluyver, E.P., Wensvoort, G., Moormann, R., 1993b. Lelystad virus, the
causative agent of porcine epidemic abortion and respiratory syndrome
(PEARS), is related to LDV and EAV. Virology 192, 62–72.
Meulenberg, J., Bos-De Ruijter, J.N., Wensvoort, G., Moormann, R., 1998. An
infectious cDNA clone of porcine reproductive and respiratory syndrome
virus. Adv. Exp. Med. Biol. 440, 199–206.
429Y. Wang et al. / Virology 371 (2008) 418–429Murtaugh, M., Faaberg, K., Laber, J., Elam, M., Kapur, V., 1998. Genetic
variation in the PRRS virus. Adv. Exp. Med. Biol. 440, 787–794.
Nelsen, C., Murtaugh, M., Faaberg, K., 1999. Porcine reproductive and
respiratory syndrome virus comparison: divergent evolution on two
continents. J. Virol. 73, 270–280.
Nielsen, H., Liu, G., Nielsen, J., Oleksiewicz, M., Botner, A., Storgaard, T.,
Faaberg, K., 2003. Generation of an infectious clone of VR-2332, a highly
virulent North American-type isolate of porcine reproductive and respiratory
syndrome virus. J. Virol. 77, 3702–3711.
Oleksiewicz, M., Botner, A., Nielsen, J., Storgaard, T., 1999. Determination of
5′-leader sequences from radically disparate strains of porcine reproductive
and respiratory syndrome virus reveals the presence of highly conserved
sequence motifs. Arch. Virol. 144, 981–987.
Pesch, S., Meyer, C., Ohlinger, V., 2005. New insights into the genetic diversity
of European porcine reproductive and respiratory syndrome virus (PRRSV).
Vet. Microbiol. 107, 31–48.
Pham, Q., Biacchesi, S., Skiadopoulos, M., Murphy, B., Collins, P., Buchholz,
U., 2005. Chimeric recombinant human metapneumoviruses with the
nucleoprotein or phosphoprotein open reading frame replaced by that of
avian metapneumovirus exhibit improved growth in vitro and attenuation in
vivo. J. Virol. 79, 15114–15122.
Plana-Duran, J., Bastons, M., Urniza, A., Vayreda, M., Vila, X., Mane, H., 1997.
Efficacy of an inactivated vaccine for prevention of reproductive failure
induced by porcine reproductive and respiratory syndrome virus. Vet.
Microbiol. 55, 361–370.
Pletnev, A., Swayne, D., Speicher, J., Rumyantsev, A., Murphy, B., 2006.
Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation
in mice, geese and monkeys for safety and immunogenicity. Vaccine 24,
6392–6404.
Schommer, S., Kleiboeker, S., 2006. Use of a PRRSVinfectious clone to evaluate
in vitro quasispecies evolution. Adv. Exp. Med. Biol. 581, 435–438.
Skiadopoulos, M., Tatem, J., Surman, S., Mitcho, Y., Wu, S., Elkins, W.,
Murphy, B., 2002. The recombinant chimeric human parainfluenza virustype 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and
protective in African green monkeys. Vaccine 20, 1846–1852.
Snijder, E., Meulenberg, J., 1998. The molecular biology of arteriviruses. J. Gen.
Virol. 79, 961–979.
Snyder, M., Betts, R., Deborde, D., Tierney, E., Clements, M., Herrington, D.,
Sears, S., Dolin, R., Maassab, H., Murphy, B., 1988. Four viral genes
independently contribute to attenuation of live influenza A/Ann Arbor/6/60
(H2N2) cold-adapted reassortant virus vaccines. J. Virol. 62, 488–495.
Truong, H., Lu, Z., Kutish, G., Galeota, J., Osorio, F., Pattnaik, A., 2004. A
highly pathogenic porcine reproductive and respiratory syndrome virus
generated from an infectious cDNA clone retains the in vivo virulence and
transmissibility properties of the parental virus. Virology 325, 308–319.
Whitehead, S., Hill, M., Firestone, C., St Claire, M., Elkins, W., Murphy, B.,
Collins, P., 1999. Replacement of the F and G proteins of respiratory
syncytial virus (RSV) subgroup A with those of subgroup B generates
chimeric live attenuated RSV subgroup B vaccine candidates. J. Virol. 73,
9773–9780.
Wu, W., Fang, Y., Farwell, R., Steffen-Bien, M., Rowland, R., Christopher-
Hennings, J., Nelson, E., 2001. A 10-kDa structural protein of porcine
reproductive and respiratory syndrome virus encoded by ORF2b. Virology
287, 183–191.
Yuan, S., Nelsen, C., Murtaugh, M., Schmitt, B., Faaberg, K., 1999.
Recombination between North American strains of porcine reproductive
and respiratory syndrome virus. Virus Res. 61, 87–98.
Yuan, S., Murtaugh, M., Faaberg, K., 2000. Heteroclite subgenomic RNAs are
produced in porcine reproductive and respiratory syndrome virus infection.
Virology 275, 158–169.
Yuan, S., Mickelson, D., Murtaugh, M., Faaberg, K., 2001. Complete genome
comparison of porcine reproductive and respiratory syndrome virus parental
and attenuated strains. Virus Res. 74, 99–110.
Yuan, S., Murtaugh, M., Schumann, F., Mickelson, D., Faaberg, K., 2004.
Characterization of heteroclite subgenomic RNAs associated with PRRSV
infection. Virus Res. 105, 75–87.
